Takeda, Eisai To Speed Cancer Drugs From Acquisitions
This article was originally published in PharmAsia News
Japanese drug makers Takeda Pharmaceutical and Eisai plan to take advantage of recent U.S. acquisitions to step up development of cancer drugs. Both firms gained access to the drugs with buys this year, Takeda with Millennium Pharmaceuticals, Eisai with MGI Pharma. Takeda plans to begin Phase II trials for its candidate this year while Eisai begins trials on a compound similar to Takeda's, for inhibiting cancer growth. In addition, Eisai is gearing up for a planned three-year expansion to quintuple that aspect of its business. (Click here for more - a subscription may be required
You may also be interested in...
The Phase III FIDELIO trial of finerenone has been a success but analysts want to see some actual data before declaring it an unqualified one.
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.